Prognostic Analysis of Different Treatment Options for Cerebral Hemorrhage

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorThe Affiliated Hospital Of Guizhou Medical University

About this trial

To analyze the influence of early hematoma morphology on hematoma expansion, optimize the treatment plan for cerebral hemorrhage, and guide the treatment of patients with cerebral hemorrhage in combination with clinical practice.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Age 18-80 years old;

Intracerebral hemorrhage was diagnosed by head CT examination;

Disqualifiers

Multiple intracranial hemorrhage;

Intracranial hemorrhage caused by intracranial tumor, aneurysm, trauma, infarction or other lesions;

Coagulation disorders or a history of taking anticoagulants;

Infectious meningitis, systemic infection;

Trial population

The inpatients admitted to the Emergency Neurology Department of the Affiliated Hospital of Guizhou Medical University from January 1, 2014 to August 31, 2022 were collected. According to the head CT at the time of admission, they were divided into the hematoma rule group and the hematoma irregular group

Trial design

Design model

Case-control

Time perspective

Retrospective

Treatments tested in this trial

  • Stereotactic intracranial hematoma puncture

    Procedure/Surgery

    Check the CT scan of the patient's brain, find out the largest hematoma level of the patient, measure the coordinates of the puncture center, locate and mark the skull surface according to the coordinates obtained from the measurement, select the puncture point under the stereotaxic instrument, and mainly avoid important blood vessels , nerves and functional areas. Use an electric drill to drill the puncture needle into the center of the hematoma, and slowly aspirate the hematoma from the side hole until the suction stops when there is resistance. The residual hematoma in CT and the location of the drainage tube were determined, and the position of the puncture needle was adjusted for the situation of brain CT. After the operation, according to the re-examination of cranial CT, urokinase was injected into the hematoma cavity through the drainage tube to dissolve the residual hematoma, and the operation process strictly followed aseptic operation.

  • decompressive craniectomy

    Procedure/Surgery

    Prior to the procedure, all patients obtained endotracheal intubation under general anesthesia following the informed consent provided by their family members. Upon identifying the hematoma's location through CT imaging, the surgeon made a linear or horseshoe-shaped incision on the scalp and subsequently opened the dura mater after creating a bone flap. The hematoma was punctured using a brain needle, allowing for effective decompression. The cerebral cortex was incised along the cerebral gyri, facilitating the separation of brain tissue to eliminate residual hematoma. Once hemostasis was ensured within the operative area, a silicone drainage tube was inserted, and the cranial bone flap was restored to its original position. In cases of severe brain edema or cerebral herniation, bone flap decompression was performed.

  • Neuroendoscopic

    Procedure/Surgery

    The patient's preoperative CT and MR imaging data were fused with a neuronavigation system to avoid important functional areas and select the closest point of the hematoma to the cortex as the location point. Routine craniotomy was performed with a 2\*3 cm bone window, the puncture direction was repositioned by neuronavigation, the sheath was placed at the center of the hematoma, the core was removed, the endoscope was gradually aspirated, and the bleeding was stopped with electrocoagulation if there was considerable active bleeding. A drainage tube was placed, the bone flap was reset after surgery, and the scalp was sutured.

Treatment groups

1,000 Participants
are divided into 4 treatment groups
Group A: Stereotactic intracranial hematoma puncture treatment group1 intervention
Group B: drug treatment group0 interventions
Group C: decompressive craniectomy treatment group1 intervention
Group D: Neuroendoscopic treatment group1 intervention

Trial outcomes

Primary outcomes

1

Hematoma expansion rate 24 hours after onset

The number of cases with enlarged hematoma after re-examination of head CT after 24 hours

Time frame
24 hours of onset
2

90-day Modified Rankin Rating Scale score;

Modified Rankin Rating Scale score at 90 days after discharge,0-3 indicates good prognosis, 4-6 indicates poor prognosis, and 6 indicates death.

Time frame
90-day

Secondary outcomes

1

90-day mortality

Proportion of patients who died 90 days after discharge

Time frame
90-day

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.